Frexalimab, a Second-Generation Anti-CD40 Ligand Antibody: Prolonged Kidney Allograft Survival in Non-Human Primates with Subcutaneous Maintenance Administration (ATC 2026) - Jun 17, 2026 - Abstract #Abstract 1100; Pres time: Jun 23, 2026; 04:18 PM - 04:30 PM; Location: 205A' Level 2; "These data demonstrate that frexalimab, an anti-CD40L, without other immunosuppressive agents, is effective and safe at preventing rejection in a NHP transplantation model. This supports the advancement of frexalimab's clinical development program in kidney transplantation."
Clinical • Cardiovascular • CNS Disorders • Cytomegalovirus Infection • Diabetes • Glomerulonephritis • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Metabolic Disorders • Multiple Sclerosis • Nephrology • Systemic Lupus Erythematosus • Type 1 Diabetes Mellitus • CD40LG
|
|
P. Severy 1; J. L. Vela 1; I. Mochkin 2; J. Voss 3; E. Poulton 1; A. Vergani 1; C. Radosti 3
|